Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Search
Partnering Days
Partnering Days
Respiratory
Respiratory
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Manufacturing & Supply Chain
Manufacturing & Supply Chain
Brazil
Brazil
Dubai
Dubai
Research Beyond Borders
Research Beyond Borders
Information Technology
IT
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Human Health Partnering
Human Health Partnering
Parasiticides
Parasiticides
Technologies
Technologies
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Cardio-Renal-Metabolic diseases
Cardio-Renal-Metabolic diseases
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
Mental Health disorders
Mental Health disorders
Our People, Our Culture
Our People, Our Culture
We’re All In
We’re All In
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Vaccines
Vaccines
Animal Health Partnering
Animal Health Partnering
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Metabolic Diseases
CardioMetabolic Disease Research